Prophylactic antibiotic days as a predictor of sensitivity patterns in acinetobacter pneumonia

Surgical Infections

Volumn 12, Issue 1, 2011, Pages 33-38

  Amin, Parth B ^a   Magnotti, Louis J ^a   Fischer, Peter E ^a   Fabian, Timothy C ^a   Croce, Martin A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CILASTATIN PLUS IMIPENEM; COLISTIMETHATE; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TRANSFUSION; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; FIBEROPTIC BRONCHOSCOPY; GLASGOW COMA SCALE; HUMAN; INFECTION PREVENTION; INJURY SCALE; LIMB INJURY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; COMA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; TIME FACTORS; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 79951537625     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2010.036     Document Type: Article

References (22)

1. Siempos II, Vardakas KZ, Kyriakopoulos CE, et al. Predictors of mortality in adult patients with ventilator-associated pneumonia: A meta-analysis. Shock 2009 Nov 26 [Epub ahead of print].
2. Magnotti LJ, Croce MA, Fabian TC. Is ventilator-associated pneumonia in trauma patients an epiphenomenon or a cause of death? Surg Infect 2004;5:237-242. (Pubitemid 39462166)
3. Hidron AI, Edwards JR, Patel J, et al.; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. National Healthcare Safety Network annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
4. Croce MA, Fabian TC, Waddle-Smith L, Maxwell RA. Identification of early predictors for post-traumatic pneumonia. Am Surg 2001;65:105-110.
5. Croce MA, Fabian TC, Schurr MJ, et al. Using bronch-oalveolar lavage to distinguish nosocomial pneumonia from SIRS: A prospective analysis. J Trauma 1995;39:1134-1139.
6. Magnotti LJ, Schroeppel TJ, Fabian TC, et al. Reduction in inadequate antibiotic therapy for ventilator-associated pneumonia: Impact of a unit-specific treatment pathway. Am Surg 2008;74:516-522. (Pubitemid 351768762)
7. Harrison PF, Lederberg J (eds). Antimicrobial Resistance: Issues and Options. Institute of Medicine. Washington, D.C. National Academy Press, 1998:8-74.
8. Rosenthal VD, Maki DG, Mehta A, et al.; International Noso-comial Infection Control Consortium Members. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008;36:627-637.
9. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-582.
10. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358:1271-1281.
11. Towner KJ. Acinetobacter: An old friend, but a new enemy. J Hosp Infect 2009;73:355-363.
12. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64(Suppl 1):i29-i36.
13. Falagas ME, Kasiaskou KA, Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27.
14. Livermore DM, Hill RL, Thomson H, et al.; C-MRAB Study Group. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acineto-bacter baumannii around London. Int J Antimicrob Agents 2010;35:19-24.
15. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicrob Chemother 2007;59:128-131. (Pubitemid 46017915)
16. Paterson DL. ''Collateral damage'' from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(Suppl 4):S341-S345. (Pubitemid 38669889)
17. Villers D, Espaze E, Coste-Burel M, et al. Nosocomial Aci-netobacter baumannii infections: Microbiological and clinical epidemiology. Ann Intern Med 1998;129:182-189. (Pubitemid 28377507)
18. Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009;29:1054-1060.
19. Mohr AM, Sifri ZC, Horng HS, et al. Use of aerosolized aminoglycosides in the treatment of gram-negative ventilator-associated pneumonia. Surg Infect 2007;8:349-357. (Pubitemid 47186305)
20. Kelleghan SI, Salemi C, Padilla S, et al. An effective continuous quality improvement approach to the prevention of ventilator-associated pneumonia. Am J Infect Control 1993;21:322-330. (Pubitemid 24020090)
21. Wip C, Napolitano L. Bundles to prevent ventilator-associated pneumonia: How valuable are they? Curr Opin Infect Dis 2009;2:159-166.
22. Bochicchio GV, Napolitano L, Joshi M, et al. Blood product transfusion and ventilator-associated pneumonia in trauma patients. Surg Infect 2008;9:415-422.